Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Data submitted by Theravance/Astellas in response to an October FDA “approvable” letter for the antibiotic could be behind the agency’s decision.
Advertisement

Related Content

Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
Astellas Announces 32 Percent Earnings Increase For Fiscal 2007
FDA Wants More Ceftobiprole Data From J&J/Basilea
FDA Stalls J&J’s Doribax For Hospital-Acquired Pneumonia
FDA Anti-Infective Drugs Advisory Committee To Review Two Antibiotics
Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA
Theravance/Astellas Antibiotic Telavancin “Approvable” At FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS067299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel